Charles River Laboratories Intl (CRL) 57.09 $CRL
In Vitro Toxicity Testing to Grow at a 15.84% CAGR to 2018 Says a New Research Report at ReportsnReports.com
PRWeb - Mon Apr 14, 2:58AM CDT
Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as Cruelty-free food Cosmetics And clothing as cruelty-free testing does not damage the environment or produce harmful waste. Analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. According to the report, the Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Covered in this Report The Global In Vitro Toxicity Testing market can be divided into four end-user segments: Cosmetics and Personal Care Industry, Pharmaceuticals Industry, Food Industry, and Chemicals Industry. The Global In Vitro Toxicity Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the market. In addition, the report discusses the major drivers that influence the growth of the Global In Vitro Toxicity Testing market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Accelrys Inc. Bio-Rad Laboratories Inc. Charles River Laboratories International Inc. Covance Inc. Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=280671. Other Prominent Vendors Entelos Inc. Mattek Corp. Molecular Toxicology Inc. RTI Health Solutions SBW Ltd. Smithers Group Inc. Xenobiotic Detection Systems Inc. Xenometrix AG Key Market Driver Increasing Opposition to Animal Testing. Key Market Challenge Concerns about Accuracy and Reliability of the Test. Key Market Trend Increase in Animal-free Testing Campaigns. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The report recognizes the following companies as the key players in Global In-vitro Toxicity Testing Market: Accelrys Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc. , Covance Inc. , Entelos Inc., MattekCorp., Molecular Toxicology Inc., RTI Health Solutions, SBW Ltd., Smithers Group Inc., Xenobiotic Detection SystemsInc., Xenometrix AG. Key Questions Answered in this Report What will the market size be in 2018 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
Charles River Laboratories Schedules First-Quarter 2014 Earnings Release and Conference Call
Business Wire - Mon Apr 07, 3:15PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2014 financial results on Wednesday, April 30th, after the market closes. A conference call has been scheduled to discuss this information on Thursday, May 1st, at 9:00 a.m. ET.
Pivotal Study Positive Results, Appointments, Proposed Public Offerings, Financial Results, and Product Launches - Analyst Notes on Amgen, Humana, Aetna, Perrigo, and Charles River
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN),
Jim Cramer's 'Mad Money' Recap: Hope Springs Eternal
at The Street - Wed Apr 02, 7:24PM CDT
Investors are hopeful the economy is really improving, and that's why some stocks are surging again, Cramer says.
Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts
M2 - Tue Apr 01, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnnrlm/healthcare_bpo) has announced the addition of the "Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts" report to their offering. The global healthcare BPO market is dominated by the U.S. A very large percentage of the healthcare BPO requirement arises out of the U.S. Europe is quickly emerging as another important source segment in this market. The U.S. and India are the two largest destination geographies. Philippines and Eastern Europe are two of the fastest growing destination segments in this market. The payer market is segmented into claims processing, member services, HR services, and finance and accounts segments. Claims processing is an important service segment in the payer outsourcing market. It is further sub-divided into claims indexing, claims investigation, claims adjudication, claims repricing, claims settlement, litigation management, and information management. The provider market is segmented into medical billing, medical coding, medical transcription, and finance and account segments. The pharmaceutical outsourcing market is segmented into contract research organizations (CRO), contract manufacturing organizations (CMO), and business support services. Each service segment in the pharmaceutical outsourcing market is divided into further sub-segments. The CRO service segment is sub-divided into drug discovery, pre-clinical, clinical phases I, II, III and IV, clinical data management and biostatistics, medical writing, regulatory services, and non-clinical functions. The CMO service segment is sub-divided into API manufacturing, and formulation and packaging. The non-clinical service segment is sub-divided into supply chain management and logistics, sales and marketing, and non-clinical functions. The report also highlights the marketing KPO function in the sales and marketing outsourcing segment. Scope Healthcare BPO Market Payer - Claims Processing - HR Services - Finance & Accounts Provider - Medical Billing & Coding Pharmaceutical - Clinical Trial - Contract Manufacturing - Non-Clinical Services Key Topics Covered: - Introduction - Executive Summary - Market Overview - Healthcare Payer Outsourcing Market - Healthcare Provider Outsourcing Market - Pharmaceutical Outsourcing Market - Geographical Analysis - Competitive Landscape - Company Profiles - Accenture Plc - Accretive Health, Inc. - Anthelio Healthcare Solutions, Inc. - Boehringer Ingelheim Gmbh - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. - Cognizant Technology Solutions Corporation - Covance, Inc. - Gebbs Healthcare Solutions, Inc. - Genpact Limited - Ibm Corporation - Icon Plc - Igate Patni - Infosys Bpo Limited - Inventiv Health Inc - Lonza Group Ltd. - Medusind Solutions Inc - Mphasis Limited - Omega Healthcare Management Services Pvt Ltd - Parexel International Corporation - Patheon Inc - Pharmaceutical Product Development, Inc. - Piramal Enterprises Limited - Quintiles Transnational Holdings, Inc. - Tata Consultancy Services Ltd - Tech Mahindra - Teleradiology Solutions Pvt Ltd. - Wns (Holdings) Limited - Xerox Corporation Visit http://www.researchandmarkets.com/research/hn...thcare_bpo
Charles River Laboratories and Galapagos complete transaction
GlobeNewswire - Tue Apr 01, 12:36AM CDT
Galapagos NV (Euronext: GLPG) confirms the completion of the transaction announced on 13 March 2014 to sell the BioFocus and Argenta service division operations to Charles River Laboratories International, Inc. (NYSE: CRL) for a total consideration of up to EUR134 million.
Charles River Laboratories Completes the Acquisition of the CRO Services Division of Galapagos NV
Business Wire - Mon Mar 31, 7:48PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.
Interesting CRL Put And Call Options For November 22nd
DividendChannel.com - Wed Mar 26, 9:54AM CDT
Investors in Charles River Laboratories International Inc. saw new options begin trading this week, for the November 22nd expiration.
Health Care Equities Movers and Shakers -- Research on Quintiles Transnational, PerkinElmer, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Mar 25, 9:05AM CDT
The trading session on Monday, March 24, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,276.69, down 0.16% and the NASDAQ Composite closed at 4,226.39, down 1.18%. The S&P 500 finished the session 0.49% lower at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41% and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Quintiles Transnational Holdings Inc. (NYSE: Q), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on Q, PKI, PRXL and CRL can be downloaded upon signing up at:
Jim Cramer's Top Stock Picks: CRL TSLA EOG
at The Street - Wed Mar 19, 5:00AM CDT
Cramer is a fan of EOG Resources and says Charles River Labs is a great way to play the biotechs.
Jim Cramer's 'Mad Money' Recap: Profits Still Matter
at The Street - Tue Mar 18, 7:07PM CDT
Once the hedge fund managers realized there was no bad news coming from Russia or China, they started buying U.S. stocks, Cramer says.
FDA Approvals, Definitve Agreements, Prestigious Recognitions, and Stock Summaries - Analyst Notes on Mallinckrodt, Novo Nordisk, Charles River Laboratories, Cerner, and Quintiles
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), Charles River Laboratories International, Inc. (NYSE: CRL), Cerner Corporation (NASDAQ: CERN), and Quintiles Transnational Holdings Inc. (NYSE: Q). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Charles River Acquires CRO Division of Galapagos - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:40PM CDT
In a move to advance its position in the fast-growing outsourced discovery services market, Charles River Laboratories entered into a definitive agreement to acquire the CRO services division of Galapagos NV.
Charles River Aims To Be 'One-Stop Shop' With Buyout
at Investor's Business Daily - Thu Mar 13, 10:39AM CDT
Contract research organization Charles River Laboratories (CRL) said Thursday that it's agreed to buy the CRO business of Belgian drugmaker Galapagos NV. Charles River stock touched a more than five-year high in early trading on the stock market...
Charles River Laboratories acquires CRO services division of Galapagos for EUR129m cash
M2 - Thu Mar 13, 7:07AM CDT
Drug development company Charles River Laboratories International Inc (NYSE:CRL) announced today that it has entered into a definitive agreement to acquire the CRO (contract research organisation) services division of Galapagos NV (FRA: GXE.F) (OTC: GLPGF), which includes both Argenta and BioFocus.
3 Stocks Breaking Out on Big Volume
at The Street - Thu Mar 13, 5:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to EUR134 million
Thomson Reuters ONE - Thu Mar 13, 1:46AM CDT
-- Total cash consideration of up to EUR134 million
Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV
Business Wire - Thu Mar 13, 1:45AM CDT
--- Transaction Expected to be Accretive to Non-GAAP EPS by $0.10 in 2014 -
In Vitro Toxicity Testing to Grow at a 15.84% CAGR to 2018 Says a New Research Report at ReportsnReports.com
PRWeb - Mon Apr 14, 2:58AM CDT
Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as Cruelty-free food Cosmetics And clothing as cruelty-free testing does not damage the environment or produce harmful waste. Analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. According to the report, the Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Covered in this Report The Global In Vitro Toxicity Testing market can be divided into four end-user segments: Cosmetics and Personal Care Industry, Pharmaceuticals Industry, Food Industry, and Chemicals Industry. The Global In Vitro Toxicity Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the market. In addition, the report discusses the major drivers that influence the growth of the Global In Vitro Toxicity Testing market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Accelrys Inc. Bio-Rad Laboratories Inc. Charles River Laboratories International Inc. Covance Inc. Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=280671. Other Prominent Vendors Entelos Inc. Mattek Corp. Molecular Toxicology Inc. RTI Health Solutions SBW Ltd. Smithers Group Inc. Xenobiotic Detection Systems Inc. Xenometrix AG Key Market Driver Increasing Opposition to Animal Testing. Key Market Challenge Concerns about Accuracy and Reliability of the Test. Key Market Trend Increase in Animal-free Testing Campaigns. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The report recognizes the following companies as the key players in Global In-vitro Toxicity Testing Market: Accelrys Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc. , Covance Inc. , Entelos Inc., MattekCorp., Molecular Toxicology Inc., RTI Health Solutions, SBW Ltd., Smithers Group Inc., Xenobiotic Detection SystemsInc., Xenometrix AG. Key Questions Answered in this Report What will the market size be in 2018 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
Charles River Laboratories Schedules First-Quarter 2014 Earnings Release and Conference Call
Business Wire - Mon Apr 07, 3:15PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2014 financial results on Wednesday, April 30th, after the market closes. A conference call has been scheduled to discuss this information on Thursday, May 1st, at 9:00 a.m. ET.
Pivotal Study Positive Results, Appointments, Proposed Public Offerings, Financial Results, and Product Launches - Analyst Notes on Amgen, Humana, Aetna, Perrigo, and Charles River
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN),
Jim Cramer's 'Mad Money' Recap: Hope Springs Eternal
at The Street - Wed Apr 02, 7:24PM CDT
Investors are hopeful the economy is really improving, and that's why some stocks are surging again, Cramer says.
Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts
M2 - Tue Apr 01, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnnrlm/healthcare_bpo) has announced the addition of the "Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts" report to their offering. The global healthcare BPO market is dominated by the U.S. A very large percentage of the healthcare BPO requirement arises out of the U.S. Europe is quickly emerging as another important source segment in this market. The U.S. and India are the two largest destination geographies. Philippines and Eastern Europe are two of the fastest growing destination segments in this market. The payer market is segmented into claims processing, member services, HR services, and finance and accounts segments. Claims processing is an important service segment in the payer outsourcing market. It is further sub-divided into claims indexing, claims investigation, claims adjudication, claims repricing, claims settlement, litigation management, and information management. The provider market is segmented into medical billing, medical coding, medical transcription, and finance and account segments. The pharmaceutical outsourcing market is segmented into contract research organizations (CRO), contract manufacturing organizations (CMO), and business support services. Each service segment in the pharmaceutical outsourcing market is divided into further sub-segments. The CRO service segment is sub-divided into drug discovery, pre-clinical, clinical phases I, II, III and IV, clinical data management and biostatistics, medical writing, regulatory services, and non-clinical functions. The CMO service segment is sub-divided into API manufacturing, and formulation and packaging. The non-clinical service segment is sub-divided into supply chain management and logistics, sales and marketing, and non-clinical functions. The report also highlights the marketing KPO function in the sales and marketing outsourcing segment. Scope Healthcare BPO Market Payer - Claims Processing - HR Services - Finance & Accounts Provider - Medical Billing & Coding Pharmaceutical - Clinical Trial - Contract Manufacturing - Non-Clinical Services Key Topics Covered: - Introduction - Executive Summary - Market Overview - Healthcare Payer Outsourcing Market - Healthcare Provider Outsourcing Market - Pharmaceutical Outsourcing Market - Geographical Analysis - Competitive Landscape - Company Profiles - Accenture Plc - Accretive Health, Inc. - Anthelio Healthcare Solutions, Inc. - Boehringer Ingelheim Gmbh - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. - Cognizant Technology Solutions Corporation - Covance, Inc. - Gebbs Healthcare Solutions, Inc. - Genpact Limited - Ibm Corporation - Icon Plc - Igate Patni - Infosys Bpo Limited - Inventiv Health Inc - Lonza Group Ltd. - Medusind Solutions Inc - Mphasis Limited - Omega Healthcare Management Services Pvt Ltd - Parexel International Corporation - Patheon Inc - Pharmaceutical Product Development, Inc. - Piramal Enterprises Limited - Quintiles Transnational Holdings, Inc. - Tata Consultancy Services Ltd - Tech Mahindra - Teleradiology Solutions Pvt Ltd. - Wns (Holdings) Limited - Xerox Corporation Visit http://www.researchandmarkets.com/research/hn...thcare_bpo
Charles River Laboratories and Galapagos complete transaction
GlobeNewswire - Tue Apr 01, 12:36AM CDT
Galapagos NV (Euronext: GLPG) confirms the completion of the transaction announced on 13 March 2014 to sell the BioFocus and Argenta service division operations to Charles River Laboratories International, Inc. (NYSE: CRL) for a total consideration of up to EUR134 million.
Charles River Laboratories Completes the Acquisition of the CRO Services Division of Galapagos NV
Business Wire - Mon Mar 31, 7:48PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.
Interesting CRL Put And Call Options For November 22nd
DividendChannel.com - Wed Mar 26, 9:54AM CDT
Investors in Charles River Laboratories International Inc. saw new options begin trading this week, for the November 22nd expiration.
Health Care Equities Movers and Shakers -- Research on Quintiles Transnational, PerkinElmer, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Mar 25, 9:05AM CDT
The trading session on Monday, March 24, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,276.69, down 0.16% and the NASDAQ Composite closed at 4,226.39, down 1.18%. The S&P 500 finished the session 0.49% lower at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41% and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Quintiles Transnational Holdings Inc. (NYSE: Q), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on Q, PKI, PRXL and CRL can be downloaded upon signing up at:
Jim Cramer's Top Stock Picks: CRL TSLA EOG
at The Street - Wed Mar 19, 5:00AM CDT
Cramer is a fan of EOG Resources and says Charles River Labs is a great way to play the biotechs.
Jim Cramer's 'Mad Money' Recap: Profits Still Matter
at The Street - Tue Mar 18, 7:07PM CDT
Once the hedge fund managers realized there was no bad news coming from Russia or China, they started buying U.S. stocks, Cramer says.
FDA Approvals, Definitve Agreements, Prestigious Recognitions, and Stock Summaries - Analyst Notes on Mallinckrodt, Novo Nordisk, Charles River Laboratories, Cerner, and Quintiles
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), Charles River Laboratories International, Inc. (NYSE: CRL), Cerner Corporation (NASDAQ: CERN), and Quintiles Transnational Holdings Inc. (NYSE: Q). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Charles River Acquires CRO Division of Galapagos - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:40PM CDT
In a move to advance its position in the fast-growing outsourced discovery services market, Charles River Laboratories entered into a definitive agreement to acquire the CRO services division of Galapagos NV.
Charles River Aims To Be 'One-Stop Shop' With Buyout
at Investor's Business Daily - Thu Mar 13, 10:39AM CDT
Contract research organization Charles River Laboratories (CRL) said Thursday that it's agreed to buy the CRO business of Belgian drugmaker Galapagos NV. Charles River stock touched a more than five-year high in early trading on the stock market...
Charles River Laboratories acquires CRO services division of Galapagos for EUR129m cash
M2 - Thu Mar 13, 7:07AM CDT
Drug development company Charles River Laboratories International Inc (NYSE:CRL) announced today that it has entered into a definitive agreement to acquire the CRO (contract research organisation) services division of Galapagos NV (FRA: GXE.F) (OTC: GLPGF), which includes both Argenta and BioFocus.
3 Stocks Breaking Out on Big Volume
at The Street - Thu Mar 13, 5:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to EUR134 million
Thomson Reuters ONE - Thu Mar 13, 1:46AM CDT
-- Total cash consideration of up to EUR134 million
Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV
Business Wire - Thu Mar 13, 1:45AM CDT
--- Transaction Expected to be Accretive to Non-GAAP EPS by $0.10 in 2014 -
